Vertex Pharmaceuticals Aktie
377,30
EUR
-54,70
EUR
-12,66
%
395,49
USD
-1,08
USD
-0,27
%
nachbörslich
Vertex Pharmaceuticals Aktie Analyse
| 26.10.18 | Vertex Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 01.10.18 | Vertex Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 07.08.18 | Vertex Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
| 05.03.18 | Vertex Pharmaceuticals Buy | Maxim Group | |
| 01.02.18 | Vertex Pharmaceuticals overweight | Barclays Capital | |
| 18.10.17 | Vertex Pharmaceuticals Outperform | RBC Capital Markets | |
| 29.09.17 | Vertex Pharmaceuticals Buy | BTIG Research | |
| 15.09.17 | Vertex Pharmaceuticals Outperform | RBC Capital Markets | |
|
Werbung
|
|||
| 19.07.17 | Vertex Pharmaceuticals overweight | Barclays Capital | |
| 18.07.17 | Vertex Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
| 23.06.17 | Vertex Pharmaceuticals Buy | Needham & Company, LLC | |
| 31.03.17 | Vertex Pharmaceuticals Outperform | BMO Capital Markets | |
| 31.03.17 | Vertex Pharmaceuticals Buy | Maxim Group | |
| 29.03.17 | Vertex Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
| 09.03.17 | Vertex Pharmaceuticals Buy | UBS AG | |
| 26.01.17 | Vertex Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
| 15.09.16 | Vertex Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
| 28.04.16 | Vertex Pharmaceuticals overweight | Barclays Capital | |
| 28.04.16 | Vertex Pharmaceuticals Outperform | RBC Capital Markets | |
| 08.04.16 | Vertex Pharmaceuticals Market Perform | BMO Capital Markets | |
| 01.04.16 | Vertex Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
| 18.03.16 | Vertex Pharmaceuticals Outperform | RBC Capital Markets | |
| 01.12.15 | Vertex Pharmaceuticals Buy | Stifel, Nicolaus & Co., Inc. | |
| 30.10.15 | Vertex Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 28.09.15 | Vertex Pharmaceuticals Buy | Argus Research Company | |
| 14.09.15 | Vertex Pharmaceuticals overweight | Barclays Capital | |
| 23.06.15 | Vertex Pharmaceuticals Outperform | RBC Capital Markets | |
| 10.04.15 | Vertex Pharmaceuticals Buy | Canaccord Adams | |
| 29.01.15 | Vertex Pharmaceuticals Buy | Deutsche Bank AG | |
| 01.12.14 | Vertex Pharmaceuticals Buy | Maxim Group | |
| 06.11.14 | Vertex Pharmaceuticals Buy | CRT Capital | |
| 29.10.14 | Vertex Pharmaceuticals Outperform | RBC Capital Markets | |
| 10.10.14 | Vertex Pharmaceuticals Buy | Maxim Group | |
| 17.09.14 | Vertex Pharmaceuticals Buy | Deutsche Bank AG | |
| 05.12.12 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 02.11.12 | Vertex Pharmaceuticals buy | UBS AG | |
| 02.11.12 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 12.10.12 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 13.09.12 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 30.08.12 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 02.08.12 | Vertex Pharmaceuticals buy | Banc of America Securities-Merrill Lynch | |
| 01.08.12 | Vertex Pharmaceuticals outperform | Credit Suisse Group | |
| 31.07.12 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 31.07.12 | Vertex Pharmaceuticals buy | UBS AG | |
| 27.07.12 | Vertex Pharmaceuticals kaufen | Fuchsbriefe | |
| 02.07.12 | Vertex Pharmaceuticals outperform | RBC Capital Markets | |
| 12.06.12 | Vertex Pharmaceuticals overweight | Barclays Capital | |
| 28.05.12 | Vertex Pharmaceuticals overweight | Barclays Capital | |
| 09.05.12 | Vertex Pharmaceuticals overweight | Barclays Capital | |
| 08.05.12 | Vertex Pharmaceuticals buy | Needham & Company, LLC | |